Cancer Research Meeting Calendar  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 3422, April 1, 2007. doi: 10.1158/0008-5472.CAN-06-2836
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heemers, H. V.
Right arrow Articles by Tindall, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heemers, H. V.
Right arrow Articles by Tindall, D. J.

Endocrinology

Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells

Hannelore V. Heemers1, Thomas J. Sebo2, Jose D. Debes1, Kevin M. Regan1, Kristin A. Raclaw1, Linda M. Murphy2, Alfred Hobisch3, Zoran Culig4 and Donald J. Tindall1

1 Departments of Urology/Biochemistry and Molecular Biology and 2 Laboratory Medicine/Pathology, Mayo Clinic, Rochester, Minnesota; 3 Department of Urology, General Hospital Feldkirch, Feldkirch, Austria; and 4 Department of Urology, Innsbruck Medical University, Innsbruck, Austria

Requests for reprints: Donald J. Tindall, Department of Urology/Biochemistry and Molecular Biology, Mayo Clinic, Guggenheim 1742, 200 1st Street SW, Rochester, MN 55905. Phone: 507-284-8138; Fax: 507-284-2384; E-mail: tindall.donald{at}mayo.edu.

Standard therapy for nonorgan confined prostate cancer aims to block the production or action of androgens. Although initially successful, antiandrogen therapy eventually fails and androgen depletion independent (ADI) disease emerges. Remarkably, ADI prostate cancers still rely on a functional androgen receptor (AR). Aberrant expression of coregulatory proteins required for the formation of productive AR transcriptional complexes is critical for ADI AR activation. Previously, we have shown that the transcriptional coactivator p300 is required for ADI activation of the AR and is up-regulated in prostate cancer, in which its expression is associated with cell proliferation and predicts aggressive tumor features. The mechanism responsible for the deregulated expression of p300, however, remains elusive. Here, we show that p300 expression in prostate cancer cells is subject to androgen regulation. In several prostate cancer model systems, addition of synthetic and natural androgens led to decreased expression of p300 in a time-dependent and dose-dependent manner. Experiments using AR antagonists or small interfering RNA targeting the AR revealed that down-regulation of p300 depends entirely on the presence of a functional AR. It is noteworthy that androgens down-regulated p300 protein expression while leaving messenger levels unaltered. Conversely, both short-term and long-term androgen deprivation resulted in marked up-regulation of p300 expression. The androgen deprivation–induced increase in p300 expression was not affected by the addition of cytokines or growth factors or by cotreatment with antiandrogens. Moreover, increased p300 expression upon androgen starvation is crucial for prostate cancer cell proliferation, as loss of p300 expression severely reduces expression of cyclins governing G1-S and G2-M cell cycle transition and decreases 5-bromo-2'-deoxyuridine incorporation. [Cancer Res 2007;67(7):3422–30]




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. X. Zou, L. Guo, A. S. Revenko, C. G. Tepper, A. T. Gemo, H.-J. Kung, and H.-W. Chen
Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer
Cancer Res., April 15, 2009; 69(8): 3339 - 3346.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H. V. Heemers, K. M. Regan, L. J. Schmidt, S. K. Anderson, K. V. Ballman, and D. J. Tindall
Androgen Modulation of Coregulator Expression in Prostate Cancer Cells
Mol. Endocrinol., April 1, 2009; 23(4): 572 - 583.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S. A Boorjian, H. V Heemers, I. Frank, S. A Farmer, L. J Schmidt, T. J Sebo, and D. J Tindall
Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder
Endocr. Relat. Cancer, March 1, 2009; 16(1): 123 - 137.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Bawa-Khalfe, J. Cheng, Z. Wang, and E. T. H. Yeh
Induction of the SUMO-specific Protease 1 Transcription by the Androgen Receptor in Prostate Cancer Cells
J. Biol. Chem., December 28, 2007; 282(52): 37341 - 37349.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
H. V. Heemers and D. J. Tindall
Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex
Endocr. Rev., December 1, 2007; 28(7): 778 - 808.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.